XXXX Use During Breastfeeding.

@entity1 @entity304 @entity16 @entity245 @entity3812
UNASSIGNED: Objective: This study evaluated the outcome of @entity1 exposed to @entity3812 during lactation. Subjects and Methods: A prospective observational cohort study design was used. Mothers who contacted Beilinson Teratology Information Service (BELTIS) regarding use of @entity3812 while breastfeeding were followed up by phone interview. Data on lactation, neonatal symptoms, and outcome 1-3 years after initial consultation were obtained. Mothers breastfeeding while taking @entity3812 (n=37) and their @entity1 (n=38) were compared with a matched control group of mothers using a drug known to be safe during lactation (n=75) and their @entity1 (n=76). Results: Follow-up was obtained for 59 of 76 (78%) @entity1 who contacted BELTIS regarding use of @entity3812 . Of the 59 @entity1 , 37 breastfed while taking @entity3812 , five did not take @entity3812 , 16 did not breastfeed, and one declined to participate. The mean duration of breastfeeding was similar in both groups. @entity304 were seen in three of 38 @entity3812 -exposed @entity1 versus four of 76 of control group @entity1 (p=0.68). @entity245 or @entity16 were seen in two @entity1 in both study groups (p=0.60). None of the @entity3812 -exposed @entity1 showed abnormal growth. Conclusions: No increase in adverse long-term outcomes was found in @entity3812 -exposed breastfed @entity1 . Our data support continuation of breastfeeding in @entity1 treated with @entity3812 .
